TTRX (Turn Therapeutics) Treasury Stock: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $9.39
! 1 Warning Sign
View Full Analysis

What is Turn Therapeutics Treasury Stock?

Turn Therapeutics TTRX -1.26% 11 Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Turn Therapeutics's treasury stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Turn Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics Treasury Stock Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Treasury Stock
0.00 0.00 0.00

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
TTRX
11GF Score
Turn Therapeutics Inc TTRX
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turn Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Turn Therapeutics (TTRX) has a Treasury Stock of $0.00 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Turn Therapeutics and its competitors.
Is Turn Therapeutics' Treasury Stock too high?
Turn Therapeutics' current Treasury Stock is $0.00 Mil. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' Treasury Stock compare to IRD and VRXA?
Turn Therapeutics' Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Turn Therapeutics and its competitors. Turn Therapeutics's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Turn Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.39
Price